Abstract

BackgroundA pair of genes is defined as synthetically lethal if defects on both cause the death of the cell but a defect in only one of the two is compatible with cell viability. Ideally, if A and B are two synthetic lethal genes, inhibiting B should kill cancer cells with a defect on A, and should have no effects on normal cells. Thus, synthetic lethality can be exploited for highly selective cancer therapies, which need to exploit differences between normal and cancer cells.ResultsIn this paper, we present a new method for predicting synthetic lethal (SL) gene pairs. As neighbouring genes in the genome have highly correlated profiles of copy number variations (CNAs), our method clusters proximal genes with a similar CNA profile, then predicts mutually exclusive group pairs, and finally identifies the SL gene pairs within each group pairs. For mutual-exclusion testing we use a graph-based method which takes into account the mutation frequencies of different subjects and genes. We use two different methods for selecting the pair of SL genes; the first is based on the gene essentiality measured in various conditions by means of the “Gene Activity Ranking Profile” GARP score; the second leverages the annotations of gene to biological pathways.ConclusionsThis method is unique among current SL prediction approaches, it reduces false-positive SL predictions compared to previous methods, and it allows establishing explicit collateral lethality relationship of gene pairs within mutually exclusive group pairs.

Highlights

  • A pair of genes is defined as synthetically lethal if defects on both cause the death of the cell but a defect in only one of the two is compatible with cell viability

  • Data We run our pipeline on a set copy number variations (CNAs) experiments from cBioPortal [15] that comprises the patients of TCGA provisional studies on bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COADREAD), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), brain lower grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), prostate adenocarcinoma (PRAD) and thyroid carcinoma (THCA)

  • We present here the results obtained by applying our method to a large dataset of CNA from many patients and compare our predictions with the one provided by the standard procedure based on the hypergeometric test

Read more

Summary

Introduction

A pair of genes is defined as synthetically lethal if defects on both cause the death of the cell but a defect in only one of the two is compatible with cell viability. Synthetic lethality can be exploited for highly selective cancer therapies, which need to exploit differences between normal and cancer cells. Doxorubicin, which interferes with the DNA thereby stopping DNA replication in rapidly dividing cancer cells, can cause congestive heart failure [1]. The severity of such side effects may outweigh the benefits of these therapeutic. SL, first defined by Bridges [2] in 1922, refers to the genetic relationship between two (or more) genes where simultaneous genetic defects in both (or all) genes cause cell death but a defect in only one of the genes alone is compatible with cell viability [3, 4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call